5‐aminosalicylate–intolerant patients are at increased risk of colectomy for ulcerative colitis

• DOI: 10.1111/apt.16120
• Publication Date: 2023-09-03T09:39:19Z
• Authors: Shuji Hibiya; Yusuke Matsuyama; Toshimitsu Fujii; Chiaki Maeyashiki; Eiko Saito; Kimiko Ito; Hiromichi Shimizu; Ami Kawamoto; Maiko Motobayashi; Kento Takenaka; Masakazu Nagahori; Masayuki Kurosaki; Tsunehito Yauchi; Kazuo Ohtsuka; Takeo Fujiwara; Ryuichi Okamoto; Mamoru Watanabe
• Keywords: Medical record

Summary Background Although 5‐aminosalicylate (5‐ASA) is the therapy of first choice in ulcerative colitis (UC), some patients cannot tolerate it because side effects. Previous reports have not investigated whether 5‐ASA intolerance associated with risk colectomy. Aim To investigate associations between tolerance and colectomy among UC Methods The data who visited any three hospitals during 2014‐2018 around Tokyo, Japan, were retrospectively obtained from medical records. Patients categorized as (a) tolerant to compounds (“tolerant 5‐ASA”) (b) intolerant one or more leading refrainment their further use (“intolerant 5‐ASA”). association was examined by Cox proportional hazards model adjusted for sex, age, smoking extent colitis. Results Of 1788 patients, 1684 “tolerant 5‐ASA” while 104 “intolerant 5‐ASA”. Colectomy performed 43 (2.6%) 12 (11.5%) 5‐ASA. After adjusting all covariates, undergoing higher group than (hazard ratio: 4.92; 95% confidence interval: 2.58‐9.38). Conclusion whom discontinued due had a first, second third compounds.